Anixa Biosciences, Inc. (ANIX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.0700 |
| Open | 3.1300 |
| Bid | 3.0800 x 1200 |
| Ask | 3.2800 x 800 |
| Day's Range | 3.0700 - 3.2800 |
| 52 Week Range | 2.7100 - 8.0900 |
| Volume | |
| Avg. Volume | 169,450 |
| Market Cap | 93.41M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4530 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
Fair Value
Related Research
- Anixa Biosciences, Inc.Analyst Report: Charles River Laboratories International, Inc.Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.RatingFair ValueEconomic Moat21 hours agoMorningstar
- PR Newswire
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines." The technology was invented by Drs. Vincent K. Tuohy, Suparna Mazumder and Justin M. Johnson at Cleveland Clinic. Anixa is the worldwide licensee for the vaccine technology. Patents for the technology were issued in
- PR Newswire
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer's PAXLOVID™, which was recently authorized to treat COVID-19. PAXLOVID also includes ritonavir, wh
- PR Newswire
Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022.
